Pharmacokinetic, Safety, and Efficacy Effects of Oral LBH589 on Dextromethorphan in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer or Malignant Pleural Mesothelioma

Study Overview
=================
Brief Summary
-----------------
This study will investigate the effect of oral LBH589 on dextromethorphan, a CYP2D6 substrate, and to assess safety and efficacy of oral LBH589 when used with this co-medication in advanced stage NSCLC or malignant pleural mesothelioma patients

Official Title
-----------------
A Phase IB, Open-Label, Multicenter Study to Investigate the Effect of Oral LBH589 on Dextromethorphan, a CYP2D6 Substrate, and to Assess the Efficacy and Safety of Oral LBH589 in Patients With Advanced Solid Tumors

Conditions
-----------------
Carcinoma, Non-Small-Cell Lung, Mesothelioma

Intervention / Treatment
-----------------
* Drug: LBH589


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Age ≥ 18 years Must have histologically or cytologically confirmed advanced or metastatic incurable solid tumor as documented by CT or MRI that has progressed on or following standard therapies Must have failed prior standard systemic therapy Must have at least one measurable and/or non-measurable lesion as defined by RECIST criteria Baseline MUGA or ECHO must demonstrate LVEF ≥ the lower limit of the institutional normal. Written informed consent obtained prior to any screening procedures Willingness to have multiple blood draws Ability to swallow capsules or tablets Exclusion criteria: Uncontrolled brain metastases Prior treatment with an HDAC inhibitor Presence of clinically detectable third-space fluid collections (e.g., ascites or pleural effusions) that can not be controlled by drainage or other procedures prior to study entry Concomitant use of any anti-cancer therapy, including radiation therapy Significant cardiac disease Concomitant use of drugs with a risk of causing torsades de pointes Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral LBH589 Previous use of monoamine oxidase inhibitors (e.g. clorgyline, iproniazid, isocarboxazid, moclobemide, sibutramine, phenelzine, tranylcypromine) within 14 days prior to the first dose of dextromethorphan

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: LBH589<br> | Drug: LBH589<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Pharmacokinetic (PK) parameters |  | first 10 days | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Response rate assessed by comparing tumor size via radiology scans (CTs or MRIs) |  | day 10 through end of treatment | 
| Safety (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation |  | first 10 days, day 10 through end of treatment plus follow-up | 
| Tolerability (until disease progression, unacceptable toxicity or study completion) assessed by duration of patient participation |  | day 10 through end of treatment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Non-small cell lung cancer, NSCLC, lung cancer, pleural mesothelioma, malignant, advanced stage, mesothelioma, phase I, LBH589, dextromethorphan, CYP2D6, oral